Literature DB >> 15569988

Associations between serum testosterone fall and cognitive function in prostate cancer patients.

Eeva K Salminen1, Raija I Portin, Aki Koskinen, Hans Helenius, Martti Nurmi.   

Abstract

Data on the association between cognition and testosterone levels in elderly men are inconclusive. Androgen deprivation therapy is commonly used in the treatment of prostate cancer with the aim of achieving castration levels of serum testosterone. The study group comprised 26 elderly men (mean age 65 years) with newly diagnosed prostate cancer. Cognitive testing was done at baseline and at 6 and 12 months on androgen deprivation therapy. Cognitive performances were evaluated using verbal, visuomotor, and memory tests as well as tests of processing speed and attention. Castration levels of testosterone were achieved in all patients by 6 months. Significant associations between cognitive performances and testosterone decline were documented: visuomotor slowing, slowed reaction times in some attentional domains including working memory and impaired hit rate in a vigilance test, impaired delayed recall and recognition speed of letters, but improvement in object recall. The results suggest selective associations between testosterone decline and cognition. Documentation of cognitive performance with changes in serum testosterone levels has substantial implications for informed patient support in prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15569988     DOI: 10.1158/1078-0432.CCR-04-0750

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  42 in total

1.  Cardiac and cognitive effects of androgen deprivation therapy: are they real?

Authors:  S M H Alibhai; H Z Mohamedali
Journal:  Curr Oncol       Date:  2010-09       Impact factor: 3.677

Review 2.  Role of androgens and the androgen receptor in remodeling of spine synapses in limbic brain areas.

Authors:  Tibor Hajszan; Neil J MacLusky; Csaba Leranth
Journal:  Horm Behav       Date:  2007-12-31       Impact factor: 3.587

3.  Second-to-fourth digit ratio predicts success among high-frequency financial traders.

Authors:  John M Coates; Mark Gurnell; Aldo Rustichini
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-12       Impact factor: 11.205

Review 4.  What are critical outcome measures for patients receiving pituitary replacement following brain injury?

Authors:  Sorin G Beca; Walter M High; Brent E Masel; Kurt A Mossberg; Randall J Urban
Journal:  Pituitary       Date:  2012-03       Impact factor: 4.107

5.  Depressive symptomatology in men receiving androgen deprivation therapy for prostate cancer: a controlled comparison.

Authors:  Morgan Lee; Heather S Jim; Mayer Fishman; Babu Zachariah; Randy Heysek; Matthew Biagioli; Paul B Jacobsen
Journal:  Psychooncology       Date:  2014-06-13       Impact factor: 3.894

Review 6.  Management of complications of androgen deprivation therapy in the older man.

Authors:  Supriya G Mohile; Karen Mustian; Kathryn Bylow; William Hall; William Dale
Journal:  Crit Rev Oncol Hematol       Date:  2008-10-25       Impact factor: 6.312

Review 7.  Cognitive effects of hormone therapy in men with prostate cancer: a review.

Authors:  Christian J Nelson; Jennifer S Lee; Maria C Gamboa; Andrew J Roth
Journal:  Cancer       Date:  2008-09-01       Impact factor: 6.860

8.  A randomized controlled trial of add-back estrogen or placebo on cognition in men with prostate cancer receiving an antiandrogen and a gonadotropin-releasing hormone analog.

Authors:  Rose H Matousek; Barbara B Sherwin
Journal:  Psychoneuroendocrinology       Date:  2009-07-16       Impact factor: 4.905

9.  The benefits and risks of testosterone replacement therapy: a review.

Authors:  Nazem Bassil; Saad Alkaade; John E Morley
Journal:  Ther Clin Risk Manag       Date:  2009-06-22       Impact factor: 2.423

10.  Changes in neuronal activation patterns in response to androgen deprivation therapy: a pilot study.

Authors:  Monique M Cherrier; Paul R Borghesani; Amy L Shelton; Celestia S Higano
Journal:  BMC Cancer       Date:  2010-01-04       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.